Revolution Financial Statements From 2010 to 2025

RVMDW Stock   0.10  0.01  9.09%   
Revolution Medicines, financial statements provide useful quarterly and yearly information to potential Revolution Medicines, Warrant investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Revolution Medicines, financial statements helps investors assess Revolution Medicines,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Revolution Medicines,'s valuation are summarized below:
Gross Profit
-592.2 M
Revenue
742 K
Revenue Per Share
0.005
There are over one hundred nineteen available trending fundamental ratios for Revolution Medicines,, which can be analyzed over time and compared to other ratios. All traders should should check out Revolution Medicines,'s recent fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 7.7 B in 2025. Enterprise Value is likely to climb to about 7.3 B in 2025

Revolution Medicines, Total Revenue

0.0

Check Revolution Medicines, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines,'s main balance sheet or income statement drivers, such as Net Interest Income of 91.2 M, Interest Income of 91.2 M or Interest Expense of 331 K, as well as many indicators such as Price To Sales Ratio of 265, Dividend Yield of 0.0 or PTB Ratio of 3.08. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines, Valuation or Volatility modules.
  
Check out the analysis of Revolution Medicines, Correlation against competitors.

Revolution Medicines, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.7 B2.6 B726.8 M
Slightly volatile
Other Current Liabilities101.4 M96.6 M21.5 M
Slightly volatile
Total Current Liabilities87.8 M163.9 M59.6 M
Slightly volatile
Total Stockholder Equity2.4 B2.3 B609.9 M
Slightly volatile
Property Plant And Equipment Net78.9 M141.8 M35.8 M
Slightly volatile
Accounts Payable32.2 M54.4 M19.4 M
Slightly volatile
Cash298.8 M543.1 M129.9 M
Slightly volatile
Non Current Assets Total169.7 M230.7 M117.1 M
Slightly volatile
Good Will11.7 M13.1 M14.3 M
Slightly volatile
Common Stock Shares Outstanding101.5 M167.7 M70.7 M
Slightly volatile
Short Term Investments1.8 B1.7 B442.9 M
Slightly volatile
Non Current Liabilities Total86.6 M129.2 M49 M
Slightly volatile
Capital Lease Obligations71 M135.8 M28.8 M
Slightly volatile
Other Current Assets40.2 M38.3 M9.6 M
Slightly volatile
Total Liabilities174.4 M293.1 M108.6 M
Slightly volatile
Property Plant And Equipment Gross93.3 M163.6 M44.8 M
Slightly volatile
Total Current Assets2.4 B2.3 B605.1 M
Slightly volatile
Capital Stock17.1 K18 K190.7 M
Slightly volatile
Non Current Liabilities Other797.5 K670 K690.2 K
Pretty Stable
Net Working Capital2.3 B2.2 B538.4 M
Slightly volatile
Intangible Assets47.5 M56.7 M60.1 M
Slightly volatile
Short and Long Term Debt Total85.2 M135.8 M49.9 M
Slightly volatile
Cash And Short Term Investments1.3 B2.3 B718.1 M
Slightly volatile
Liabilities And Stockholders Equity1.5 B2.6 B868.3 M
Slightly volatile
Other Stockholder Equity2.2 BB1.2 B
Slightly volatile
Short Term Debt11 M12.9 M6.1 M
Slightly volatile
Common Stock12.8 K18 K8.8 K
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile

Revolution Medicines, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income91.2 M86.9 M16.7 M
Slightly volatile
Interest Income91.2 M86.9 M16.8 M
Slightly volatile
Interest Expense331 K348.4 K725.1 K
Slightly volatile
Selling General Administrative51.9 M97.3 M30.8 M
Slightly volatile
Research Development311.4 M592.2 M188 M
Slightly volatile
Total Operating Expenses363.3 M689.5 M218.7 M
Slightly volatile
Reconciled Depreciation9.1 M11.8 M6.5 M
Slightly volatile
Depreciation And AmortizationM10.7 M7.4 M
Slightly volatile
Other Operating Expenses320 M573.6 M224.6 M
Slightly volatile
Cost Of Revenue496.6 M472.9 M178.3 M
Slightly volatile
Total Other Income Expense Net93.1 M88.7 M16.4 M
Slightly volatile
Selling And Marketing Expenses2.6 M2.9 M3.1 M
Slightly volatile

Revolution Medicines, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation83.2 M79.2 M21.5 M
Slightly volatile
Begin Period Cash Flow734.1 M699.2 M167.9 M
Slightly volatile
Capital Expenditures7.5 M10.3 M4.5 M
Slightly volatile
Issuance Of Capital Stock459 M846.3 M332.6 M
Slightly volatile
Total Cash From Financing Activities635.8 M959.4 M403.2 M
Slightly volatile
End Period Cash Flow302.5 M546.8 M136.1 M
Slightly volatile
Sale Purchase Of Stock2.8 MM1.5 M
Slightly volatile
Other Cashflows From Financing Activities212.4 M113.1 M75.3 M
Slightly volatile
Change To Account Receivables1.9 M1.3 M2.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio26525292.4856
Slightly volatile
PTB Ratio3.083.2389119
Slightly volatile
Days Sales Outstanding75.4645.4599.3748
Slightly volatile
Book Value Per Share14.1813.50444.6222
Slightly volatile
Stock Based Compensation To Revenue5.044.81.0883
Slightly volatile
PB Ratio3.083.2389119
Slightly volatile
EV To Sales21520580.8243
Slightly volatile
Payables Turnover0.390.411.496
Pretty Stable
Sales General And Administrative To Revenue6.175.881.6069
Slightly volatile
Research And Ddevelopement To Revenue34.5332.899.0741
Slightly volatile
Capex To Revenue0.630.60.2009
Slightly volatile
Cash Per Share14.3313.64814.5548
Slightly volatile
Days Payables Outstanding678926832
Slightly volatile
Intangibles To Total Assets0.02650.02790.3038
Slightly volatile
Net Debt To EBITDA0.580.59060.5274
Slightly volatile
Current Ratio8.5214.20036.3995
Slightly volatile
Tangible Book Value Per Share13.7313.07954.1215
Slightly volatile
Receivables Turnover4.938.314.519
Slightly volatile
Shareholders Equity Per Share14.1813.50444.6222
Slightly volatile
Debt To Equity0.04380.060.0275
Slightly volatile
Capex Per Share0.05260.06150.055
Slightly volatile
Revenue Per Share0.110.120.4778
Slightly volatile
Interest Debt Per Share0.850.80990.2923
Slightly volatile
Debt To Assets0.0370.05310.023
Slightly volatile
Price Book Value Ratio3.083.2389119
Slightly volatile
Days Of Payables Outstanding678926832
Slightly volatile
Ebt Per Ebit1.060.87140.9857
Slightly volatile
Company Equity Multiplier1.711.12942.3378
Slightly volatile
Long Term Debt To Capitalization0.04120.04630.0505
Slightly volatile
Total Debt To Capitalization0.04060.05660.0255
Slightly volatile
Debt Equity Ratio0.04380.060.0275
Slightly volatile
Quick Ratio8.5614.20036.4305
Slightly volatile
Net Income Per E B T0.780.99870.9304
Pretty Stable
Cash Ratio2.263.31312.0739
Slightly volatile
Days Of Sales Outstanding75.4645.4599.3748
Slightly volatile
Price To Book Ratio3.083.2389119
Slightly volatile
Fixed Asset Turnover0.130.11582.2414
Slightly volatile
Debt Ratio0.0370.05310.023
Slightly volatile
Price Sales Ratio26525292.4856
Slightly volatile
Asset Turnover0.00610.00650.0918
Slightly volatile
Price Fair Value3.083.2389119
Slightly volatile

Revolution Medicines, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.7 B7.3 B2.2 B
Slightly volatile
Enterprise Value7.3 B6.9 B2.1 B
Slightly volatile

Revolution Fundamental Market Drivers

Cash And Short Term Investments2.3 B

About Revolution Medicines, Financial Statements

Revolution Medicines, investors use historical fundamental indicators, such as Revolution Medicines,'s revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revolution Medicines,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-49.1 M-46.6 M
Cost Of Revenue472.9 M496.6 M
Stock Based Compensation To Revenue 4.80  5.04 
Sales General And Administrative To Revenue 5.88  6.17 
Research And Ddevelopement To Revenue 32.89  34.53 
Capex To Revenue 0.60  0.63 
Revenue Per Share 0.12  0.11 
Ebit Per Revenue(48.38)(45.96)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.